  |
Lægemiddelstofklassifikation ATC |
M | ||
  |
Antineoplastiske og immunomodulerende midler |
ML | ||
  |
antineoplastiske stoffer |
ML01 | ||
 |
monoklonale antistoffer og antistof-lægemiddel-konjugater |
ML01F | ||
|
PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) hæmmere |
ML01FF | ||
 |
nivolumab |
ML01FF01 | ||
 |
pembrolizumab |
ML01FF02 | ||
 |
durvalumab |
ML01FF03 | ||
 |
avelumab |
ML01FF04 | ||
 |
atezolizumab |
ML01FF05 | ||
 |
cemiplimab |
ML01FF06 | ||
 |
dostarlimab |
ML01FF07 | ||
 |
prolgolimab |
ML01FF08 | ||
 |
tislelizumab |
ML01FF09 | ||
 |
retifanlimab |
ML01FF10 | ||
 |
sugemalimab |
ML01FF11 | ||
 |
serplulimab |
ML01FF12 | ||
  |
toripalimab |
ML01FF13 |
TEXT